newsA combination of dexamethasone, remdesivir, and baricitinib was associated with…
11 August 2022 | By Caroline Peachey (European Pharmaceutical Review)
A combination of dexamethasone, remdesivir, and baricitinib was associated with a ‘significant survival benefit’ when compared with dual therapy of dexamethasone with remdesivir, according to a retrospective study.